Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ocrevus subcutaneous injection

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

- PMLiVE

Roche’s Hemlibra scores broader NHS funding

Expands to around 2,000 patients in England

- PMLiVE

Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

Garraway joins from Eli Lilly

Roche Basel Switzerland

Roche undercuts price of Bayer cancer drug after winning FDA approval

Both drugs highly effective in small subset of patients

- PMLiVE

Positive first-line phase 3 results for Tecentriq

Hopes to extend use in bladder cancer

- PMLiVE

Roche reveals yet another Spark takeover delay

Are concerns about haemophilia dominance the cause?

- PMLiVE

Tecfidera successor’s side-effect profile boosts Biogen

But analysts unconvinced that patients will switch

- PMLiVE

Keytruda scores in neoadjuvant triple negative breast cancer combo

Tecentriq still in pole position

Roche Basel Switzerland

New products help lift Roche outlook despite biosimilar onslaught

Two new cancer therapies approved in Q2

- PMLiVE

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Targeting largest family of proteins in cell membranes

The role of brain health in treating MS

Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health,...

Blue Latitude Health

Diagnosing MS: are we getting it right?

Multi-award-winning patient advocate, Trishna Bharadia, walks through the complications involved with an MS diagnosis, including the challenges for healthcare systems and a handful of insightful patient stories.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links